Cynomolgus monkey as a surrogate for human aldehyde oxidase metabolism of the EGFR Inhibitor BIBX1382

Drug Metabolism and Disposition

Volumn 42, Issue 10, 2014, Pages 1751-1760

  Matthew Hutzler, J ^a   Cerny, Matthew A ^a   Yang, Young Sun ^a   Asher, Constance ^a   Wong, Diane ^a   Frederick, Kosea ^a   Gilpin, Kyle ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(3 CHLORO 4 FLUOROPHENYL)AMINO] 6 [(1 METHYLPIPERIDIN 4 YL)AMINO]PYRIMIDO[5,4 DAY]PYRIMIDIN 2(4AH) ONE; ALDEHYDE OXIDASE; DRUG METABOLITE; FALNIDAMOL; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; ORGANIC COMPOUND; RALOXIFENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXPOSURE; DRUG METABOLISM; DRUG RETENTION; DRUG STRUCTURE; DRUG TRANSFORMATION; FEMALE; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER CLEARANCE; LIVER CYTOSOL; MACACA FASCICULARIS; MALE; NONHUMAN; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; RAT; RHESUS MONKEY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; BLOOD; CYTOSOL; DOG; LIVER; METABOLISM;

ALDEHYDE OXIDASE; ANIMALS; BIOLOGICAL AVAILABILITY; CYTOSOL; DOGS; ERBB RECEPTORS; HEPATOCYTES; HUMANS; LIVER; MACACA FASCICULARIS; MACACA MULATTA; ORGANIC CHEMICALS; RALOXIFENE; RATS;

EID: 84907457098     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.059030     Document Type: Article

References (29)

1. Akabane T, Tanaka K, Irie M, Terashita S, and Teramura T (2011) Case report of extensive metabolism by aldehyde oxidase in humans: pharmacokinetics and metabolite profile of FK3453 in rats, dogs, and humans. Xenobiotica 41:372-384.
2. Austin NE, Baldwin SJ, Cutler L, Deeks N, Kelly PJ, Nash M, Shardlow CE, Stemp G, Thewlis K, and Ayrton A, et al. (2001) Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica 31:677-686.
3. Beedham C (1987) Molybdenum hydroxylases: biological distribution and substrate-inhibitor specificity. Prog Med Chem 24:85-127.
4. Cubitt HE, Houston JB, and Galetin A (2011) Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Drug Metab Dispos 39:864-873.
5. Dalvie D, Xiang C, Kang P, and Zhou S (2013) Interspecies variation in the metabolism of zoniporide by aldehyde oxidase. Xenobiotica 43:399-408.
6. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
7. Diamond S, Boer J, Maduskuie TP, Jr, Falahatpisheh N, Li Y, and Yeleswaram S (2010) Speciesspecific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277-1285.
8. Dittrich Ch, Greim G, Borner M, Weigang-Köhler K, Huisman H, Amelsberg A, Ehret A, Wanders J, Hanauske A, and Fumoleau P (2002) Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 38:1072-1080.
9. Garattini E, Fratelli M, and Terao M (2008) Mammalian aldehyde oxidases: genetics, evolution and biochemistry. Cell Mol Life Sci 65:1019-1048.
10. Garattini E and Terao M (2011) Increasing recognition of the importance of aldehyde oxidase in drug development and discovery. Drug Metab Rev 43:374-386.
11. Garattini E and Terao M (2012) The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 8:487-503.
12. Hoshino K, Itoh K, Masubuchi A, Adachi M, Asakawa T, Watanabe N, Kosaka T, and Tanaka Y (2007) Cloning, expression, and characterization of male cynomolgus monkey liver aldehyde oxidase. Biol Pharm Bull 30:1191-1198.
13. Hutzler JM, Obach RS, Dalvie D, and Zientek MA (2013) Strategies for a comprehensive understanding of metabolism by aldehyde oxidase. Expert Opin Drug Metab Toxicol 9:153-168.
14. Hutzler JM, Yang YS, Albaugh D, Fullenwider CL, Schmenk J, and Fisher MB (2012) Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes. Drug Metab Dispos 40:267-275.
15. Itoh K, Yamamura M, Takasaki W, Sasaki T, Masubuchi A, and Tanaka Y (2006) Species differences in enantioselective 2-oxidations of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase. Biopharm Drug Dispos 27:133-139.
16. Kawashima K, Hosoi K, Naruke T, Shiba T, Kitamura M, and Watabe T (1999) Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats. Drug Metab Dispos 27:422-428.
17. Kaye B, Offerman JL, Reid JL, Elliott HL, and Hillis WS (1984) A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica 14:935-945.
18. Kitamura S, Sugihara K, Hosokawa R, Akagawa Y, Ohta S, and Ohta S (2001) Extremely high drug-reductase activity based on aldehyde oxidase in monkey liver. Biol Pharm Bull 24:856-859.
19. Kitamura S, Sugihara K, and Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98.
20. Klecker RW, Cysyk RL, and Collins JM (2006) Zebularine metabolism by aldehyde oxidase in hepatic cytosol from humans, monkeys, dogs, rats, and mice: influence of sex and inhibitors. Bioorg Med Chem 14:62-66.
21. Moriwaki Y, Yamamoto T, Takahashi S, Tsutsumi Z, and Hada T (2001) Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. Histol Histopathol 16:745-753.
22. Morrison RD, Blobaum AL, Byers FW, Santomango TS, Bridges TM, Stec D, Brewer KA, Sanchez-Ponce R, Corlew MM, and Rush R, et al. (2012) The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5. Drug Metab Dispos 40:1834-1845.
23. Nishimura M and Naito S (2006) Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21:357-374.
24. Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran TD (2010) Aldehyde oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 53:8441-8460.
25. Sahi J, Khan KK, and Black CB (2008) Aldehyde oxidase activity and inhibition in hepatocytes and cytosolic fractions from mouse, rat, monkey and human. Drug Metab Lett 2:176-183.
26. Solca FF, Baum A, Langkopf E, Dahmann G, Heider KH, Himmelsbach F, and van Meel JC (2004) Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J Pharmacol Exp Ther 311:502-509.
27. Strelevitz TJ, Orozco CC, and Obach RS (2012) Hydralazine as a selective probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the contribution of aldehyde oxidase to metabolic clearance. Drug Metab Dispos 40:1441-1448.
28. Sugihara K, Katsuma Y, Kitamura S, Ohta S, Fujitani M, and Shintani H (2000) Cynomolgus monkey liver aldehyde oxidase: extremely high oxidase activity and an attempt at purification. Comp Biochem Physiol C Toxicol Pharmacol 126:53-60.
29. Zhang X, Liu HH, Weller P, Zheng M, Tao W, Wang J, Liao G, Monshouwer M, and Peltz G (2011) In silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor. Pharmacogenomics J 11:15-24.